| Literature DB >> 28929385 |
J S Metcalf1, R A Dunlop1, J T Powell1, S A Banack1, P A Cox2.
Abstract
In human neuroblastoma cell cultures, non-human primates and human beings, L-serine is neuroprotective, acting through a variety of biochemical and molecular mechanisms. Although L-serine is generally classified as a non-essential amino acid, it is probably more appropriate to term it as a "conditional non-essential amino acid" since, under certain circumstances, vertebrates cannot synthesize it in sufficient quantities to meet necessary cellular demands. L-serine is biosynthesized in the mammalian central nervous system from 3-phosphoglycerate and serves as a precursor for the synthesis of the amino acids glycine and cysteine. Physiologically, it has a variety of roles, perhaps most importantly as a phosphorylation site in proteins. Mutations in the metabolic enzymes that synthesize L-serine have been implicated in various human diseases. Dosing of animals with L-serine and human clinical trials investigating the therapeutic effects of L-serine support the FDA's determination that L-serine is generally regarded as safe (GRAS); it also appears to be neuroprotective. We here consider the role of L-serine in neurological disorders and its potential as a therapeutic agent.Entities:
Keywords: ALS; Alzheimer’s Disease; L-serine; Neurodegeneration; Neuroprotection; Therapy
Mesh:
Substances:
Year: 2017 PMID: 28929385 DOI: 10.1007/s12640-017-9814-x
Source DB: PubMed Journal: Neurotox Res ISSN: 1029-8428 Impact factor: 3.911